Adalimumab level and Ab

Test/Investigation

Adalimumab level and Ab

Site(s) or Laboratory offering Test/Investigation

Referral laboratory

Units

AU/mL

Also Known as/Frequency of Test

Humira; Exemptia

Indications

Diseases such as ulcerative colitis and Crohn’s disease respond to anti-Tumour Necrosis Factor alpha (TNF-α) therapy (e.g. Adalimumab/ infliximab). During treatment some patients can generate high levels of anti-drug antibodies (ADAs) which negate therapeutic effect. The serum concentration of the drug immediately prior to re-infusion (trough level) is needed to interpret the relevance of ADAs. Please refer to specialist guidelines for monitoring

Comments/Precautions

Plasma NOT acceptable. Referred outside of EPA

Sample type

Serum

Turnaround times (TAT) Urgent/Routine/GP or OPD

2 weeks

Reference intervals (adult unless stated)

<5 AU/mL
Therapeutic values for Adalimumab (or biosimilar) vary according to pathology